Alumis (NASDAQ:ALMS) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of Alumis (NASDAQ:ALMS) in a research report report published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $32.00 price target on the stock.

Separately, Morgan Stanley began coverage on shares of Alumis in a research report on Tuesday. They set an overweight rating and a $36.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $27.50.

Alumis Stock Performance

Alumis stock opened at $12.50 on Tuesday. Alumis has a 1 year low of $10.45 and a 1 year high of $13.53.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alumis stock. Towerview LLC acquired a new position in shares of Alumis Inc. (NASDAQ:ALMS) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 310,000 shares of the company’s stock, valued at approximately $4,123,000. Alumis accounts for about 2.7% of Towerview LLC’s holdings, making the stock its 8th biggest holding. Towerview LLC owned 0.66% of Alumis as of its most recent filing with the Securities & Exchange Commission.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.